RUNNING HEAD Tanezumab Safety in OA Patients

TITLE
General Safety and Tolerability of Subcutaneous Tanezumab for Osteoarthritis: A Pooled Analysis of 3 Randomized, Placebo-Controlled Trials

AUTHORS
1. Francis Berenbaum, MD, PhD. Sorbonne Université, INSERM, AP-HP Hospital Saint Antoine, Paris, France.
2. Thomas J Schnitzer, MD, PhD. Northwestern University Feinberg School of Medicine, Chicago, Illinois.
3. Alan J Kivitz, MD. Altoona Center for Clinical Research, Duncansville, Pennsylvania.
4. Lars Viktrup, MD, PhD. Eli Lilly & Company, Indianapolis, Indiana.
5. Anne Hickman, DVM, PhD. Pfizer Inc, Groton, Connecticut.
6. Glenn Pixton, MS. Pfizer Inc, Morrisville, North Carolina.
7. Mark T Brown, MD. Pfizer Inc, Groton, Connecticut.
8. Isabelle Davignon, PhD. Pfizer Inc, Groton, Connecticut.
9. Christine R West, PhD. Pfizer Inc, Groton, Connecticut.

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/ACR.24637

This article is protected by copyright. All rights reserved
CORRESPONDENCE
Professor Francis Berenbaum, Department of Rheumatology, Sorbonne Université, INSERM CRSA,
AP-HP Hospital Saint Antoine, 184 rue du faubourg Saint-Antoine, Paris 75012, France;
francis.berenbaum@aphp.fr

COUNT
3942 words and 6 tables (limits are 3800 words and 6 tables)

DISCLOSURE
The study was sponsored by Pfizer and Eli Lilly and Company. Editorial support was provided by Matt Soulsby, PhD, CMPP of Engage Scientific Solutions and was funded by Pfizer and Eli Lilly and Company. Thomas J Schnitzer has served as a consultant to Pfizer, Lilly, AstraZeneca, and GSK. Francis Berenbaum has received grants through his institution from TRB Chemedica, MSD and Pfizer; has worked as a consultant to Novartis, MSD, Pfizer, Lilly, UCB, Abbvie, Roche, Servier, Sanofi-Aventis, Flexion Therapeutics, Expanscience, GSK, Biogen, Nordic, Sandoz, Regeneron, Gilead, Bone Therapeutics, Regulaxis, Peptinov, and 4P Pharma; has served as an instructor for Sandoz; and has served as a speaker for Novartis, MSD, Pfizer, Lilly, UCB, Abbvie, Roche, Servier, Sanofi-Aventis, Flexion Therapeutics, Expanscience, GSK, Biogen, Nordic, Sandoz, Regeneron, Gilead, and Sandoz. Alan J Kivitz owns stock in Pfizer, Amgen, Gilead, and GSK; has served as a consultant to Abbvie, Janssen, Novartis, Pfizer, Regeneron, SUN Pharma Advanced Research, Boeringher Ingelheim, and Gilead; and has served as a speaker for Celgene, Horizon, Merck. Novartis, Pfizer, Regeneron, Flexion, and Abbvie. L Viktrup is an employee of, and owns stock in, Eli Lilly & Company. A Hickman, G Pixton, I Davignon, MT Brown, and CR West are employees of, and own stock and/or options in, Pfizer.

DATA SHARING STATEMENT
Upon request, and subject to certain criteria, conditions, and exceptions (see https://www.pfizer.com/science/clinical-trials/trial-data-and-results for more information), Pfizer will provide access to individual de-identified participant data from Pfizer-sponsored global...
interventional clinical studies conducted for medicines, vaccines, and medical devices (1) for indications that have been approved in the US and/or EU or (2) in programs that have been terminated (i.e., development for all indications has been discontinued). Pfizer and Lilly will also consider requests for the protocol, data dictionary, and statistical analysis plan. Data may be requested from Pfizer trials 24 months after study completion. The de-identified participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal. To gain access, data requestors must enter into a data access agreement with Pfizer.

**ABSTRACT**

**Objective.** This pooled analysis of 3 randomized, placebo-controlled trials (16–24 week treatment; 8─24 week follow-up) assessed safety of subcutaneous tanezumab (2.5─10 mg every 8 weeks) in 1840 patients with hip or knee osteoarthritis.

**Methods.** Overall treatment-emergent adverse events (TEAEs) and TEAEs of abnormal peripheral sensation (APS) were prospectively assessed in 3 trials. Joint safety events (primary osteonecrosis, rapidly progressive osteoarthritis [RPOA], subchondral insufficiency fracture, pathological fracture; adjudicated by an independent expert committee) and TEAEs potentially associated with sympathetic neuropathy were prospectively assessed in 2 trials.

**Results.** During the treatment period, overall TEAE rates were 51.7% for placebo and 39.5─54.8% for tanezumab 2.5─10 mg; treatment discontinuation rates were 2.0% for placebo and 0%─1.3% for tanezumab. Rates of composite joint safety events (predominantly RPOA-type 1) over the treatment + follow-up period were 0% for placebo and 0.5─3.2% for tanezumab 2.5─5 mg (5 mg
was statistically greater than placebo); total joint replacement rates with tanezumab (5.9–7.0%)
were not significantly different from placebo (4.5%). Rates of TEAEs of APS (predominantly
paraesthesia and hypoaesthesia) were 2.2% for placebo and 3.2–12.8% for tanezumab 2.5–10 mg.
Rates of TEAEs potentially associated with sympathetic neuropathy (predominantly bradycardia and
orthostatic hypotension) were 0.8% for placebo and 0.5–2.8% for tanezumab 2.5–5 mg (exposure-
adjusted rates were not significantly different from placebo).

**Conclusion.** Tanezumab was generally well tolerated. TEAEs of APS (mostly mild and
transient) and joint safety events were infrequent but more common with tanezumab than placebo.
Tanezumab 2.5 mg demonstrated a more favorable safety profile than higher doses.
Clinicaltrials.gov:NCT01089725;NCT02697773;NCT02709486.
SIGNIFICANCE AND INNOVATIONS

- This analysis was the first to summarize safety across all Phase 3, placebo-controlled, osteoarthritis trials of subcutaneous tanezumab, a member of a novel and emerging class of anti-nerve growth factor therapies in development for the treatment of the signs and symptoms of osteoarthritis.

- The results demonstrate that tanezumab was generally well tolerated in most patients (rates of treatment discontinuations due to adverse events were 2.0% for placebo and 0%–1.3% for tanezumab) and there was no evidence of a sympathetic safety signal in the osteoarthritis population.

- Adverse events of APS occurred more frequently with tanezumab (3.2%–12.8%) than with placebo (2.2%) during the treatment period but were mostly mild (74.2%–85.7% among tanezumab-treated patients), none were serious, and typically resolved. The frequency of a diagnosis of peripheral polyneuropathy (by a blinded external neurologist) was similar in the tanezumab (0%–0.5%) and placebo treatment groups (0.2%).

- Joint safety events (most commonly rapidly progressive osteoarthritis type 1) were infrequent overall, but more common with tanezumab (0.5%–3.2%) than placebo (0%). Rates of joint safety events with low-dose tanezumab (2.5 mg) were not significantly different from placebo.

INTRODUCTION

Tanezumab, a monoclonal antibody against nerve growth factor (NGF), is in development for the treatment of the signs and symptoms of moderate-to-severe osteoarthritis (OA) (1). Early trials demonstrated efficacy of intravenous (IV) tanezumab in patients with OA of the knee or hip, but adverse events related to joint safety and abnormal peripheral sensation (APS) were observed in
some patients (2-11). Possible changes in sympathetic neuronal morphology were also observed in preclinical studies (12). Following partial clinical holds of all anti-NGF programs in 2010 (due to joint safety observations) and 2012 (due to preclinical sympathetic observations), Phase 3 trials of tanezumab resumed in 2015 with use of subcutaneous (SC) administration (for patient convenience), use of lower tanezumab doses, enrollment limited to patients with inadequate response to other OA treatments, restrictions on concomitant nonsteroidal anti-inflammatory drug (NSAID) use, and incorporation of comprehensive sympathetic function and joint safety screening and monitoring procedures.

Since resumption of clinical testing, tanezumab has demonstrated significant improvements in pain and function versus placebo in patients with moderate-to-severe OA and a history of inadequate response or intolerance to standard-of-care analgesics (13, 14). The current pooled analysis summarizes the general safety and tolerability of SC tanezumab in patients with moderate-to-severe OA by assessing overall treatment-emergent adverse events (TEAEs), joint safety events, TEAEs of APS, and TEAEs potentially associated with sympathetic neuropathy.

METHODS

Data sources. Data were derived from all randomized, placebo-controlled trials of SC tanezumab (administered every 8 weeks) in patients with OA of the knee or hip completed to date (n = 3). Tanezumab doses ranged from 2.5–10 mg, planned treatment periods ranged from 16–24 weeks, and safety follow-up periods ranged from 8–24 weeks (Table 1). Studies were conducted in compliance with ethical principles of the Declaration of Helsinki and all International Conference on Harmonization Good Clinical Practice Guidelines, protocols were approved by Institutional Review Boards or Independent Ethics Committees for each site, and all patients provided written informed consent.

Inclusion and exclusion criteria. Key inclusion criteria included: age ≥18 years, diagnosis of OA of the knee (A4091027) or of the hip or knee (A4091056 and A4091057) with radiographic confirmation (Kellgren-Lawrence [KL] grade ≥2), and a Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC\(^1\)) Pain score $\geq 5$ (from 0 to 10) in the index joint at baseline, a WOMAC Physical Function score $\geq 4$ (A4091027) or $\geq 5$ (A4091056 and A4091057) (from 0–10) in the index joint at baseline, and a Patient Global Assessment of OA score of “fair”, “poor”, or “very poor” at baseline. Patients were required to exhibit prior inadequate response or intolerance to other OA treatments (Table 1).

Non-analgesic medications for non-OA, non-pain conditions were permitted if the dose was stable for $\geq 30$ days prior to baseline. Occasional use of analgesics, including acetaminophen (if used for reasons other than rescue) and NSAIDs, was allowed for self-limiting conditions unrelated to OA (Table 1).

**Safety assessments.** Overall TEAEs were assessed throughout the 3 studies, with severity, seriousness, and relationship to treatment determined by investigators. Comprehensive joint safety screening and monitoring procedures were incorporated into post-2015 studies A4091056 and A4091057. Radiographs of all index and non-index hips, knees, and shoulders were obtained at screening and during the trials (week 40 for A4091056; weeks 24 and 48 for A4091057). A central reader reviewed images to assess eligibility criteria and possible joint safety events (rapidly progressive osteoarthritis [RPOA], subchondral insufficiency fractures [SIF], osteonecrosis, or pathologic fracture). Musculoskeletal examinations of all major joints and review of pain scores occurred at all study visits. Investigators assessed patients with increased persistent pain to determine if further evaluation (imaging or orthopedic consultation) was warranted. All possible joint safety events (assessed by the central reader on post-baseline images or reported as a TEAE by an investigator) and total joint replacements (TJR) were reviewed by a blinded adjudication committee of external experts. Patients with adjudicated outcomes of RPOA-type 1 or 2, SIF, primary osteonecrosis, or pathologic fracture were included in a composite joint safety endpoint. Rapidly progressive osteoarthritis type 1 was defined as a significant loss of joint space width $\geq 2$ mm (predicated on optimal joint positioning) within approximately 1 year, without gross structural

\(^{1}\)© 1996 Nicholas Bellamy. WOMAC\(^{\circledR}\) is a registered trademark of Nicholas Bellamy (CDN, EU, USA).
failure. Rapidly progressive osteoarthritis type 2 was defined as abnormal bone loss or destruction, including limited or total collapse of at least 1 subchondral surface, which is not normally present in conventional end-stage osteoarthritis (15).

Neurologic examinations including assessment of muscle strength (head and neck, upper and lower limbs), deep tendon reflexes, and sensation (index fingers and great toes), were performed at screening and all clinic visits during the 3 studies to evaluate patients for signs of peripheral neuropathy. Patients with history, diagnosis, or signs and symptoms of peripheral neuropathy were excluded from enrollment. In studies A4091056 and A4091057, neurologic consultations were performed if a TEAE suggestive of new or worsening peripheral neuropathy or a TEAE of APS was reported and met certain criteria (see footnote to Supplement 2).

Comprehensive sympathetic function screening and monitoring procedures were incorporated into post-2015 studies A4091056 and A4091057. Patients with a score >7 (from 0 to 55 [women] or 60 [men]) on the Survey of Autonomic Symptoms (SAS; questionnaire assessing presence of potential autonomic neuropathy), a diagnosis of autonomic neuropathy, or evidence of orthostatic hypotension at screening were excluded from enrollment (16). Sympathetic function was monitored during the studies through TEAE assessment, orthostatic blood pressure assessments at each visit, protocol-specified criteria for reporting TEAEs of bradycardia based on electrocardiogram (ECG), SAS questionnaires, and consultation with cardiologists and neurologists for pre-specified TEAEs potentially associated with sympathetic neuropathy (syncope, bradycardia, orthostatic hypotension, anhidrosis, and hypohidrosis).

**Statistical analysis.** Patient demographics, clinical characteristics, and treatment exposure were summarized descriptively. Incidences of overall TEAEs, TEAEs of APS, and TEAEs potentially associated with sympathetic neuropathy were summarized for the treatment and study (treatment + follow-up) periods. Joint safety was summarized for the study (treatment + follow-up) period only, since such events were relatively infrequent and an imbalance (between placebo and tanezumab
groups) in these events typically exists in both treatment and follow-up periods in previous trials of tanezumab. Supplement 1 describes full statistical methods.

RESULTS

Patients and exposure. Overall, 1840 patients were included in the analyses (placebo = 586; tanezumab: 2.5 mg = 602; tanezumab 2.5/5 mg = 219; tanezumab 5 mg = 347; tanezumab 10 mg = 86). Patients were predominantly white (80.9%), female (66.6%), and had approximate mean age and disease durations of 62.5 and 8.5 years, respectively (Table 2). Knee was designated as the index joint in 86.6% of patients. In post-2015 studies, 79.3% had ≥2 joints with a KL grade ≥2.

The mean (SD) number of doses received in the placebo and tanezumab 2.5 mg, 2.5/5 mg, 5 mg, and 10 mg arms was 2.2 (0.7), 2.3 (0.7), 2.0 (0.0), 2.6 (0.8), and 1.1 (0.3), respectively, while mean (SD) exposure was 18.1 (6.2), 18.6 (5.8), 16.2 (1.6), 21.3 (5.9), and 11.7 (2.6) weeks, respectively (tanezumab 10 mg was only utilized in study A4091027). Exposure calculations were based on study treatment periods which, due to pharmacokinetics of tanezumab, ended 8 weeks after final SC injection. Patient exposure years in the placebo and tanezumab 2.5 mg, 2.5/5 mg, 5 mg, and 10 mg arms were 202.8, 215.1, 67.9, 141.9, and 19.3, respectively.

Overall treatment-emergent adverse events. TEAEs during the treatment and full-study periods are summarized in Table 3 (A4091027, A4091056, A4091057). TEAE rates during the treatment period were 51.7% for placebo, 52.3% for tanezumab 2.5 mg, 47.0% for tanezumab 2.5/5 mg, 54.8% for tanezumab 5 mg, and 39.5% for tanezumab 10 mg. Among common TEAEs (occurring in ≥2% of patients in any group), injection site reaction (10 mg), oedema peripheral (2.5/5 mg; 5 mg), joint stiffness (2.5/5 mg), synovial cyst (10 mg), hypoesthesia (10 mg), and paraesthesia (5 mg; 10 mg) had a higher incidence (95% confidence interval [CI] of the risk difference vs placebo excluded 0) in a tanezumab group relative to placebo (data not shown).

Five deaths were reported (tanezumab 2.5 mg: cerebrovascular incident [informed by family after patient was lost to follow-up]; tanezumab 2.5/5 mg: lung cancer and suicide in follow-up period; tanezumab 5 mg: nasopharyngitis [severe cold with probable influenza virus infection] and
cardio-respiratory arrest in treatment period); none were deemed treatment-related (13, 14).

**Joint safety events.** Joint safety findings for the full study period are summarized in Table 4 (A4091056, A4091057). The proportion of patients included in the composite joint safety endpoint was 0% for placebo, 1.9% for tanezumab 2.5 mg, 0.5% for tanezumab 2.5/5 mg, and 3.2% for tanezumab 5 mg. Risk difference (95% CI) versus placebo was significantly greater for tanezumab 5 mg (3.17 [0.56, 7.18]; \( P = 0.037 \)) but not for tanezumab 2.5 mg (1.89 [−0.05, 4.71]; \( P = 0.084 \)) or tanezumab 2.5/5 mg (0.46 [−1.63, 4.47]; \( P = 0.696 \)). Observation time-adjusted incidence rates (patients with events/1000 patient-years) for the composite joint safety endpoint were 24.1, 6.2, and 37.5 for tanezumab 2.5 mg, 2.5/5 mg, and 5mg, respectively. The most common adjudicated joint safety event was RPOA (2.5 mg = 1.7%; 2.5/5 mg = 0.5%; 5 mg = 2.8%), mostly RPOA-type 1.

Among 20 tanezumab-treated patients included in the composite joint safety endpoint, 11 (55%) had the joint safety event in a knee and 9 (45%) had it in a hip. Eleven (55%) had the safety event in an index joint and 9 (45%) had it in a non-index joint. Baseline KL grade in the affected joint was 0, 1, 2, 3, or 4 for 2 (10%), 1 (5%), 7 (35%), 7 (35%), and 3 (15%) patients, respectively. Joint safety events occurred: during the treatment period (n = 3; 15%), after discontinuing the treatment period (n = 1; 5%), and after completing the treatment period (n = 16; 80%). Six of 20 (30%) patients included in the composite joint safety endpoint underwent a TJR.

TJR rates observed with tanezumab (2.5 mg = 5.9%, 2.5/5 mg = 6.8%, 5 mg = 7.0%) were not significantly different from placebo (4.5%); risk difference (95% CI) versus placebo was 1.40 (−2.17, 5.73) for tanezumab 2.5 mg (\( P = 0.443 \)), 2.37 (−2.24, 8.60) for tanezumab 2.5/5 mg (\( P = 0.333 \)), and 2.57 (−1.72, 8.10) for tanezumab 5 mg (\( P = 0.253 \)).

**TEAEs of abnormal peripheral sensation.** TEAEs of APS during the treatment and full study periods are summarized in Table 5 (A4091027, A4091056, A4091057). Rates of these TEAEs during the treatment period were higher with tanezumab (2.5 mg = 5.1%, 2.5/5 mg = 3.2%, 5 mg = 6.1%, 10 mg = 12.8%) than placebo (2.2%) and increased with increasing tanezumab dose. Paresthesia and
hypoesthesia were the most common adverse events and were reported more frequently in all tanezumab groups than in the placebo group.

Among patients experiencing a TEAE of APS during the treatment period, most had a mild adverse event (placebo = 92.3%, tanezumab 2.5 mg = 74.2%, tanezumab 2.5/5 mg = 85.7%, tanezumab 5 mg = 76.2%, tanezumab 10 mg = 81.8%), none had a severe or serious event, and only 1 (hypoesthesia in the tanezumab 5 mg group) discontinued treatment as a result.

The mean (SD)/median day of onset for TEAEs of APS during the treatment period was 45.2 (37.4)/57.0 for placebo, 57.3 (46.9)/57.0 for tanezumab 2.5 mg, 44.1 (36.6)/41.0 for tanezumab 2.5/5 mg, 71.3 (55.3)/61.0 for tanezumab 5 mg, and 53.0 (28.5)/62.0 for tanezumab 10 mg. The mean (SD)/median duration of these TEAEs was 109.9 (148.9)/29.0 days for placebo, 66.8 (81.3)/31.0 days for tanezumab 2.5 mg, 76.9 (44.2)/54.0 for tanezumab 2.5/5 mg, 41.7 (77.0)/16.0 days for tanezumab 5 mg, and 35.3 (40.7)/17.0 for tanezumab 10 mg. Except for patients in the tanezumab 10 mg group, a majority of patients had resolution of the adverse event by end of study (placebo = 12 of 13 [92.3%], tanezumab 2.5 mg = 25 of 31 [80.6%], tanezumab 2.5/5 mg = 6 of 7 [85.7%], tanezumab 5 mg = 19 of 21 [90.5%], tanezumab 10 mg = 3 of 11 [27.3%]). It should be noted (particularly regarding resolution) that data for the 10 mg dose were derived only from study A4091027, where safety follow-up was shorter (8 weeks) than in other studies (24 weeks). The overall profile of TEAEs of APS over the full study period was similar to that of the treatment period.

At last neurological examination, ≥ 92% of patients (across all groups in all 3 trials) had no new or worsened abnormalities, < 1.0% had new or worsened abnormalities deemed clinically significant, and overall findings were similar in the tanezumab and placebo groups. In studies A4091056 and A4091057, tanezumab-treated patients required neurologic consultation more frequently (1.8%–3.2%) than placebo-treated patients (1.4%; Supplement 2). Radiculopathy, mononeuropathy, and peripheral polyneuropathy were the most common diagnoses among patients with a consultation, but none occurred in > 1.3% of patients in any group and a dose-dependent response was not observed among tanezumab-treated patients. Radiculopathy and mononeuropathy were more frequent in tanezumab-treated patients (0.5%–1.3% and 0%–1.3%, respectively) than placebo-treated patients (0.4% and 0.2%, respectively), though the frequency of
Peripheral polyneuropathy was similar in the tanezumab (0%–0.5%) and placebo (0.2%) groups.

**TEAEs potentially associated with sympathetic neuropathy.** TEAEs potentially associated with sympathetic neuropathy during the treatment and full study periods are summarized in Table 6 (A4091056, A4091057). Rates of these TEAEs during the treatment period were 0.8% for placebo, 1.5% for tanezumab 2.5 mg, 0.5% for tanezumab 2.5/5 mg, and 2.8% for tanezumab 5 mg. Exposure-adjusted incidence rates (number of patients with events/1000 patient-years) were not significantly different for tanezumab (2.5 mg = 40.4, 2.5/5 mg = 14.7, 5 mg = 63.2) compared with placebo (21.4); risk difference (95% CI) versus placebo was 19 (–15.9, 54.0) for tanezumab 2.5 mg (P = 0.286), –6.6 (–42.3, 29.1) for tanezumab 2.5/5 mg (P = 0.716), and 41.8 (–6.7, 90.4) for tanezumab 5 mg (P = 0.091). Reports consisted mostly of bradycardia or orthostatic hypotension.

Among patients experiencing a TEAE potentially associated with sympathetic neuropathy during the treatment period, most had a mild adverse event (placebo = 100%, tanezumab 2.5 mg = 87.5%, tanezumab 2.5/5 mg = 100.0%, tanezumab 5 mg = 87.5%) and none had an event that was severe, serious, or led to treatment discontinuation.

The mean (SD)/median day of onset for these TEAEs during the treatment period was 127.3 (48.2)/128.0 for placebo (n = 4), 93.0 (59.2)/101.5 for tanezumab 2.5 mg (n = 8), 85.0 (NA)/85.0 for tanezumab 2.5/5 mg (n = 1), and 111.1 (71.7)/141.5 for tanezumab 5 mg (n = 8). The mean (SD)/median duration for these TEAEs was 47.8 (24.1)/45.5 days for placebo, 40.1 (55.5)/18.5 days for tanezumab 2.5 mg, 30.0 (NA)/30.0 days for tanezumab 2.5/5 mg, and 44.9 (49.0)/16.0 days for tanezumab 5 mg. All patients had resolution of the adverse event.

The overall profile of TEAEs potentially associated with sympathetic neuropathy over the full study period was similar to that of the treatment period.

The number of patients having a consultation due to a TEAE potentially associated with sympathetic neuropathy was 11 (2.1%) for placebo, 7 (1.3%) for tanezumab 2.5 mg, 5 (2.3%) for tanezumab 2.5/5 mg, and 5 (1.8%) for tanezumab 5 mg. None were diagnosed with a sympathetic neuropathy.
DISCUSSION

This pooled analysis of data from over 1,800 patients in 3 placebo-controlled studies demonstrates that SC tanezumab was well tolerated in most patients with moderate-to-severe OA of the hip or knee, and no new safety concerns were identified. TEAEs of APS were more common with tanezumab than placebo, though such events were infrequent, predominantly mild, and typically resolved without discontinuing treatment. Joint safety events, predominantly RPOA-1, were also infrequent but more common with tanezumab than placebo. Joint safety events, TEAEs of APS, and TEAEs potentially associated with sympathetic neuropathy were generally dose-dependent, with tanezumab 2.5 mg exhibiting a more favorable safety profile than higher doses.

Overall TEAEs during the treatment period occurred at similar rates in the tanezumab (39.5%-54.8%) and placebo (51.7%) groups, and most were mild. The only TEAEs that were severe, serious, or led to discontinuation during the treatment period in >1 patient in any tanezumab group were arthralgia and OA. These particular TEAEs are not unexpected given the studies enrolled patients with moderate-to-severe OA and a history of inadequate response to pharmacological OA treatment. TEAEs associated with tanezumab in this study (e.g. oedema peripheral, hypoesthesia, and paraesthesia) have been frequently reported in previous studies of tanezumab. Injection site reaction and synovial cyst were more often reported with tanezumab 10 mg than placebo, but this dose had relatively few patients since it was discontinued in post-2015 studies.

In post-2015 placebo-controlled studies analyzed here, joint safety events were more common with tanezumab (2.5 mg = 1.9%, 2.5/5 mg = 0.5%, 5 mg = 3.2%) than placebo (0%). The risk difference for the composite joint safety endpoint versus placebo was significantly greater for the tanezumab 5 mg group. Rates of TJRs, though numerically higher with tanezumab than placebo, were not significantly different among treatment groups. Rates of the composite joint safety endpoint and of TJRs were numerically lower with 2.5 mg than with 5 mg tanezumab. Due to extensive joint safety screening and monitoring procedures, it is difficult to compare the rate of joint safety events in post-2015 studies with pre-2015 studies. Similar to pre-2015 studies (where adjudication was conducted retrospectively), however, most tanezumab-treated patients analyzed by the adjudication committee in this post-2015 analysis had an outcome of normal progression of
OA (71.4%) and the most common event included in the composite joint safety endpoint was RPOA. In contrast to pre-2015 studies, RPOA-1 was more frequently reported than RPOA-2 in the current analysis, likely due to increased surveillance in post-2015 studies (10). In the current analysis, joint safety events included in the composite joint safety endpoint occurred primarily in joints that had KL grade evidence of OA at baseline, with similar frequency in both index (55%) and non-index (45%) joints. Only 3 events (15%) occurred in a joint with a baseline KL grade <2. Most events in the composite joint safety endpoint (80%) occurred after completion of the treatment period and 30% led to a TJR. Additional details on these joint events have been described previously (13, 14).

Repeated administration of high-dose NGF antibody does not affect healthy bone or joint tissue in monkeys or rodents (17). NGF antibody has not been associated with RPOA in preclinical studies, and the mechanism underlying increased rates of RPOA with tanezumab in human trials is unclear (10, 18, 19). Several mechanisms have been proposed that may explain the increased risk for joint safety events reported in tanezumab studies, including neuropathic and analgesic arthropathy, pre-existing deficits in bone integrity, and NGF-related effects on cartilage repair and load-induced bone formation (10, 20). However, patients receiving tanezumab do not exhibit a loss of protective pain sensitivity, which suggests neuropathic arthropathy is an unlikely mechanism. A description of joint safety in a long-term study of tanezumab was recently published (21), and further details of the systematic assessment of joint safety in the tanezumab clinical program, will be addressed in future publications.

Due to NGF’s ability to modulate nociceptor function, assessment of TEAEs of APS (e.g. hypoaesthesia and paraesthesia) is pertinent to agents targeting NGF (20, 22). TEAEs of APS occurred more frequently during the treatment period with tanezumab (3.2% to 12.8%) than placebo (2.2%), and occurred in a dose-dependent manner. The rates observed in this study were similar to those observed in previous trials of IV tanezumab at doses of 2.5 mg to 10 mg (typically <5 %–10%) (11, 23). However, the current analysis demonstrates that TEAEs of APS among tanezumab-treated patients during the treatment period were mostly mild (none were serious), rarely led to treatment discontinuation, and, except for the 10 mg dose (discontinued in post-2015 trials),
typically resolved. Further, neurologic examinations and consultations did not provide evidence that tanezumab increases the risk of peripheral polyneuropathy.

In a 24-week study in patients with painful OA, IV tanezumab (5 or 10 mg every 8 weeks) did not produce significant structural changes in Aδ and C fibers (assessed by intraepidermal nerve fiber density [IENF]) or changes in nerve conduction parameters compared with placebo (12). Similarly, in a 16-week study in patients with diabetic peripheral neuropathy, IV tanezumab (20 mg every 8 weeks) was not associated with significant changes in IENF density and quantitative sensory testing demonstrated that function of small and large sensory fibers of the lower extremities was not altered (24). Though completion of these previous studies was impacted by clinical hold, they support the current pooled analysis suggesting that tanezumab treatment, though associated with increased rates of transient and typically mild events of APS versus placebo, may not lead to irreversible changes in peripheral sensory function.

Possible changes in sympathetic neuronal morphology in rodents have been observed with tanezumab (25). In the current analysis, rates of TEAEs potentially associated with sympathetic neuropathy during the treatment period were higher with tanezumab (0.5%–2.8%) than placebo (0.8%). These adverse events were almost exclusively bradycardia and orthostatic hypotension. However, since the number of patients with TEAEs potentially associated with sympathetic neuropathy was low (no specific event occurred in >4 patients per group), it is difficult to make conclusions based solely on raw incidence rates. Exposure-adjusted rates were not significantly different between tanezumab and placebo groups. Further, TEAEs potentially associated with sympathetic neuropathy in tanezumab-treated patients during the treatment period were mostly mild and all resolved without treatment discontinuation. Notably, while the TEAEs included here are potentially associated with sympathetic neuropathy, they may have etiologies unrelated to sympathetic neuropathy and no patient was diagnosed with a sympathetic neuropathy following neurologic consultation.

Three studies have assessed effects of tanezumab (clinically relevant and supratherapeutic doses) on the sympathetic nervous system of adult nonhuman primates. They showed that 6-month exposure to tanezumab decreased sympathetic ganglion volume and neuron size, but such changes
were not associated with clinical signs of sympathetic dysfunction and completely reversed when treatment was discontinued (26). No adverse effects on the sympathetic control of cardiovascular function was associated with tanezumab exposure (26). These studies concluded that tanezumab administration (up to 6 months) had no adverse effects on sympathetic neuronal morphology or function and does not cause cell death in adult nonhuman primates (26). These findings, along with results from the current pooled analysis, support a conclusion that tanezumab is not associated with any significant sympathetic safety concerns.

The findings of this pooled analysis are limited by the relatively short trial durations. Most patients received only 1 dose of SC study medication in study A4091027 due to partial clinical hold, while treatment duration was 16–24 weeks (2–3 doses) in post-2015 studies. Thus, our findings may not represent long-term safety of tanezumab treatment, which will be better evaluated in comparator studies of extended duration. In addition, clinical trial settings are strictly controlled and may not fully represent real-world treatment settings. Finally, because clinical development of tanezumab 10 mg was discontinued and not included in post-2015 studies, the 10 mg arm was small (n = 86) compared with other groups (n = 219 to 602), making conclusions about this dose less robust. However, the strength of this analysis resides in the large dataset (over 1200) of tanezumab-treated patients. Additionally, the 2 post-2015 trials incorporated extensive neurological and joint safety monitoring procedures and lengthy follow-up (24 weeks) periods, allowing for comprehensive assessment of tanezumab’s neurological and joint safety during and after treatment.

Overall, SC tanezumab was well tolerated in most patients. TEAEs of APS (mostly mild and transient) and joint safety events were infrequent but more common with tanezumab (particularly at doses >2.5 mg) than placebo.

REFERENCES
1. Hefti F. Pharmacology of nerve growth factor and discovery of tanezumab, an anti-nerve growth factor antibody and pain therapeutic. Pharmacol Res 2020;154:104240.

2. Schnitzer TJ, Ekman EF, Spierings EL, Greenberg HS, Smith MD, Brown MT, et al. Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain. Ann Rheum Dis 2015;74:1202-11.

3. Ekman EF, Gimbel JS, Bello AE, Smith MD, Keller DS, Annis KM, et al. Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen. J Rheumatol 2014;41:2249-59.

4. Balanescu AR, Feist E, Wolfram G, Davignon I, Smith MD, Brown MT, et al. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial. Ann Rheum Dis 2014;73:1665-72.

5. Spierings EL, Fidelholtz J, Wolfram G, Smith MD, Brown MT, West CR. A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee. Pain 2013;154:1603-12.

6. Brown MT, Murphy FT, Radin DM, Davignon I, Smith MD, West CR. Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial. Arthritis Rheum 2013;65:1795-803.

7. Brown MT, Murphy FT, Radin DM, Davignon I, Smith MD, West CR. Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial. J Pain 2012;13:790-8.

8. Schnitzer TJ, Lane NE, Birbara C, Smith MD, Simpson SL, Brown MT. Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain. Osteoarthritis Cartilage 2011;19:639-46.

9. Lane NE, Schnitzer TJ, Birbara CA, Mokhtarani M, Shelton DL, Smith MD, et al. Tanezumab for the Treatment of Pain from Osteoarthritis of the Knee. N Engl J Med 2010;363:1521-31.
10. Hochberg MC, Tive LA, Abramson SB, Vignon E, Verburg KM, West CR, et al. When is osteonecrosis not osteonecrosis?: adjudication of reported serious adverse joint events in the tanezumab clinical development program. Arthritis & Rheumatology 2016;68:382-91.

11. Tive L, Bello AE, Radin D, Schnitzer TJ, Nguyen H, Brown MT, et al. Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip. J Pain Res 2019;12:975-95.

12. Brown MT, Herrmann DN, Goldstein M, Burr AM, Smith MD, West CR, et al. Nerve safety of tanezumab, a nerve growth factor inhibitor for pain treatment. J Neurol Sci 2014;345:139-47.

13. Schnitzer TJ, Easton R, Pang S, Levinson DJ, Pixton G, Viktrup L, et al. Effect of tanezumab on joint pain, physical function, and patient global assessment of osteoarthritis among patients with osteoarthritis of the hip or knee: a randomized clinical trial. JAMA 2019;322:37-48.

14. Berenbaum F, Blanco FJ, Guermazi A, Miki K, Yamabe T, Viktrup L, et al. Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period. Ann Rheum Dis 2020;79:800-10.

15. Miller CG, Guermazi A, Roemer F. The current status of imaging in anti-NGF clinical trials. Osteoarthritis Cartilage 2015;23 Suppl 1:S3-7.

16. Zilliox L, Peltier AC, Wren PA, Anderson A, Smith AG, Singleton JR, et al. Assessing autonomic dysfunction in early diabetic neuropathy: the Survey of Autonomic Symptoms. Neurology 2011;76:1099-105.

17. Gropp KE, Carlson CS, Evans MG, Bagi CM, Reagan WJ, Hurst SI, et al. Effects of monoclonal antibodies against nerve growth factor on healthy bone and joint tissues in mice, rats, and monkeys: histopathologic, biomarker, and microcomputed tomographic assessments. Toxicol Pathol 2018;46:408-20.

18. Xu L, Nwosu LN, Burston JJ, Millns PJ, Sagar DR, Mapp PI, et al. The anti-NGF antibody muMab 911 both prevents and reverses pain behaviour and subchondral osteoclast numbers in a rat model of osteoarthritis pain. Osteoarthritis Cartilage 2016;24:1587-95.
19. LaBranche TP, Bendele AM, Omura BC, Gropp KE, Hurst SI, Bagi CM, et al. Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model. Ann Rheum Dis 2017;76:295-302.

20. Schmelz M, Mantyh P, Malfait AM, Farrar J, Yaksh T, Tive L, et al. Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety. Pain 2019;160:2210-20.

21. Hochberg M, Carrino J, Schnitzer T, Guermazi A, Walsh D, White A, et al. Long-term safety and efficacy of subcutaneous tanezumab versus nonsteroidal antiinflammatory drugs for hip or knee osteoarthritis: a randomized trial. 2021;[ePub ahead of print].

22. Barker PA, Mantyh P, Arendt-Nielsen L, Viktrup L, Tive L. Nerve growth factor signaling and its contribution to pain. J Pain Res 2020;13:1223-41.

23. Bannwarth B, Kostine M. Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists? Drugs 2014;74:619-26.

24. Bramson C, Herrmann DN, Carey W, Keller D, Brown MT, West CR, et al. Exploring the role of tanezumab as a novel treatment for the relief of neuropathic pain. Pain Med 2015;16:1163-76.

25. Brown M, Koltzenburg M, Nguyen H, West C, Verburg K. Tanezumab does not cause sympathetic nervous system dysfunction in clinical osteoarthritis studies (P3.303). Neurology 2015;84:P3.303.

26. Belanger P, Butler P, Butt M, Bhatt S, Foote S, Shelton D, et al. From the Cover: Evaluation of the Effects of Tanezumab, a Monoclonal Antibody Against Nerve Growth Factor, on the Sympathetic Nervous System in Adult Cynomolgus Monkeys (Macaca fascicularis): A Stereologic, Histomorphologic, and Cardiofunctional Assessment. Toxicol Sci 2017;158:319-33.
Table 1. Description of studies included in the analysis

**STUDY A4091027** (clinicaltrials.gov: NCT01089725): Pre-2015 study in the United States in patients with OA of the knee. **SC treatments**: Placebo (n = 72) and tanezumab (2.5 mg = 74, 5 mg = 63, 10 mg = 86). **Duration**: 16-week treatment (2 SC doses) and 8-week safety follow-up. **Previous treatment requirements**: Unwilling or unable to take non-opiate pain medication, or have a history of inadequate pain relief with non-opiate pain medications, or are candidates for invasive interventions. **Rescue medication**: Acetaminophen ≤3000 mg/day for up to 3 days/week during treatment period; and no specified limit during follow-up. **NSAID restrictions**: As for all analgesics, limited use of NSAIDs was permitted on an occasional basis for self-limiting conditions unrelated to OA. **Notes**: As a result of clinical hold, 90.5% of treated patients received only 1 dose of study medication. A majority of these patients remained in the study for >16 weeks (70.7%).

**STUDY A4091056** (13) (clinicaltrials.gov: NCT02697773): Post-2015 study in the United States and Canada in patients with OA of the knee or hip. **SC treatments**: Placebo (n = 232) and tanezumab (2.5 mg = 231, 2.5/5 mg = 233). **Duration**: 16-week treatment (2 SC doses) and 24-week safety follow-up. **Previous treatment requirements**: A history of inadequate pain relief with acetaminophen; and a history of inadequate pain relief with, or contraindication/intolerability to, oral NSAIDs; and a history of inadequate pain relief with, or contraindication/intolerability to, tramadol or opioids (or unwilling to take opioids). **Rescue medication**: Acetaminophen ≤3000 mg/day for up to 3 days/week during treatment period and then up to daily during follow-up. **NSAID restrictions**: Limited use of NSAIDs was permitted on an occasional basis for self-limiting conditions unrelated to OA. Aggregate use of NSAIDs during each 8-week SC dosing interval was not to exceed 10 days and total NSAID use was not to exceed 30 days between baseline visit and 16 weeks after last SC dose. **Notes**: Overall, 87.5% and 79.9% of patients completed the treatment and full study (treatment + follow-up) periods, respectively.
STUDY A4091057 (14) (clinicaltrials.gov: NCT02709486): Post-2015 study in Europe and Japan in patients with OA of the knee or hip. SC treatments*: Placebo (n = 282) and tanezumab (2.5 mg = 283, 5 mg = 284). Duration: 24-week treatment (3 SC doses) and 24-week safety follow-up.

Previous treatment requirements: Same as study A4091056. Rescue medication: Acetaminophen ≤4000 mg/day for up to 5 days/week during treatment period and then up to daily during follow-up.

NSAID restrictions: Same as study A4091056 except total NSAID use was not to exceed 40 days between baseline visit and 16 weeks after last SC dose. Notes: Overall, 88.3% and 82.0% of patients completed the treatment and full study periods, respectively.

* In all trials, SC study medication was administered every 8 weeks.
† This study also included an intravenous tanezumab 10 mg arm which is not included in the current analyses. Patients in SC arms received intravenous doses of placebo to match the intravenous tanezumab arm.
‡ Patients were given a 2.5 mg dose at baseline and a 5 mg dose at week 8. Of the 233 patients randomized to the 2.5/5 mg treatment group, 14 received only the baseline (2.5 mg) dose and are therefore included in the tanezumab 2.5 mg treatment group in subsequent analyses/data tables.

NSAID = nonsteroidal anti-inflammatory drug; OA = osteoarthritis; SC = subcutaneous.

Table 2. Patient demographics and clinical characteristics

| Characteristic                  | Placebo (N = 586) | SC Tanezumab 2.5 mg (N = 602) | SC Tanezumab 2.5/5 mg (N = 219) | SC Tanezumab 5 mg (N = 347) | SC Tanezumab 10 mg (N = 86) |
|--------------------------------|-------------------|-------------------------------|-------------------------------|----------------------------|----------------------------|
| Mean (SD) age, years           | 62.3 (10.2)       | 62.9 (9.5)                    | 61.3 (9.1)                    | 64.3 (10.5)                 | 58.2 (8.7)                 |
| Gender, N (%)                  |                   |                               |                               |                             |                            |
| Male                           | 186 (31.7)        | 199 (33.1)                    | 80 (36.5)                     | 118 (34.0)                  | 32 (37.2)                  |
| Female | 400 (68.3) | 403 (66.9) | 139 (63.5) | 229 (66.0) | 54 (62.8) |
|--------|------------|------------|------------|------------|-----------|
| Race, N (%) | White | 463 (79.0) | 494 (82.1) | 159 (72.6) | 299 (86.2) | 73 (84.9) |
| Black or African American | 70 (11.9) | 54 (9.0) | 48 (21.9) | 8 (2.3) | 10 (11.6) |
| Asian | 49 (8.4) | 47 (7.8) | 8 (3.7) | 36 (10.4) | 2 (2.3) |
| Other/unknown | 4 (0.7) | 7 (1.2) | 4 (1.8) | 4 (1.2) | 1 (1.2) |
| BMI, N (%) | <25 kg/m² | 62 (10.6) | 88 (14.6) | 27 (12.3) | 44 (12.7) | 7 (8.1) |
| 25 to <30 kg/m² | 183 (31.2) | 188 (31.2) | 71 (32.4) | 110 (31.7) | 18 (20.9) |
| 30 to <35 kg/m² | 191 (32.6) | 196 (32.6) | 74 (33.8) | 129 (37.2) | 41 (47.7) |
| ≥35 kg/m² | 150 (25.6) | 130 (21.6) | 47 (21.5) | 64 (18.4) | 20 (23.3) |
| Index Joint, N (%) | - | | | | |
| Hip | 80 (13.7) | 88 (14.6) | 30 (13.7) | 48 (13.8) | 0 |
| Knee | 506 (86.3) | 514 (85.4) | 189 (86.3) | 299 (86.2) | 86 (100.0) |
| KL grade of index joint, N (%) | - | | | | |
| 0 | 0 | 2 (0.3) | 0 | 0 | 0 |
| 1 | 0 | 1 (0.2) | 0 | 0 | 0 |
| 2 | 157 (26.8) | 144 (23.9) | 56 (25.6) | 83 (23.9) | 40 (46.5) |
| 3 | 247 (42.2) | 270 (44.9) | 98 (44.7) | 152 (43.8) | 34 (39.5) |
| 4 | 182 (31.1) | 185 (30.7) | 64 (29.2) | 112 (32.3) | 12 (14.0) |
| Number of joints (index and non-index) with KL grade ≥2, N (%) | - | | | | |
| 0 | 0 | 0 | 0 | 0 | 0 |
| 1 | 101 (19.6) | 126 (23.9) | 45 (20.5) | 48 (16.9) | - |
| 2 | 278 (54.1) | 286 (54.2) | 116 (53.0) | 166 (58.5) | - |
| 3 | 87 (16.9) | 68 (12.9) | 34 (15.5) | 48 (16.9) | - |
|                | Study 1 | Study 2 | Study 3 | Study 4 | Study 5 |
|----------------|---------|---------|---------|---------|---------|
| OA disease duration, years | 48 (9.3) | 48 (9.1) | 24 (11.0) | 22 (7.7) | -       |
| Mean (SD) baseline WOMAC Pain score | 8.9 (8.4) | 8.0 (7.9) | 9.0 (7.3) | 8.0 (7.6) | 9.0 (10.5) |
| Mean (SD) baseline WOMAC Physical Function score | 7.0 (1.1) | 7.0 (1.2) | 7.3 (1.2) | 6.8 (1.1) | 7.5 (1.3) |

* Index joint was defined as the most painful joint at baseline with a qualifying WOMAC Pain score and KL grade as confirmed by a central reader.

† KL grade of non-index hips and knees was only assessed in studies A4091056 and A4091057.

BMI = body-mass index; KL = Kellgren-Lawrence; SC = subcutaneous; SD = standard deviation; WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index.
Table 3. Summary of overall treatment-emergent adverse events

| AEs                          | Placebo (N = 586) | SC Tanezumab 2.5 mg (N = 602) | SC Tanezumab 2.5/5 mg (N = 219) | SC Tanezumab 5 mg (N = 347) | SC Tanezumab 10 mg (N = 86) |
|------------------------------|-------------------|-------------------------------|--------------------------------|----------------------------|----------------------------|
| **During the treatment period** |                   |                               |                                |                            |                            |
| Number of AEs                | 647               | 684                           | 209                            | 482                        | 78                         |
| Patients with an AE, N (%)   | 303 (51.7)        | 315 (52.3)                    | 103 (47.0)                     | 190 (54.8)                 | 34 (39.5)                  |
| Patients with serious AE, N (%) | 9 (1.5)           | 13 (2.2)                      | 3 (1.4)                        | 9 (2.6)                    | 0                          |
| Patients with severe AE, N (%) | 10 (1.7)          | 13 (2.2)                      | 6 (2.7)                        | 13 (3.7)                   | 0                          |
| Patients discontinuing treatment due to an AE, N (%) | 12 (2.0)          | 8 (1.3)                       | 1 (0.5)                        | 4 (1.2)                    | 0                          |
| **Common AEs, N (%)**        |                   |                               |                                |                            |                            |
| Arthralgia                   | 67 (11.4)         | 52 (8.6)                      | 19 (8.7)                       | 30 (8.6)                   | 4 (4.7)                    |
| Nasopharyngitis              | 33 (5.6)          | 44 (7.3)                      | 11 (5.0)                       | 23 (6.6)                   | 0                          |
| Back pain                    | 22 (3.8)          | 28 (4.7)                      | 6 (2.7)                        | 18 (5.2)                   | 0                          |
| Headache                     | 27 (4.6)          | 26 (4.3)                      | 7 (3.2)                        | 14 (4.0)                   | 5 (5.8)                    |
| Paresthesia                  | 6 (1.0)           | 14 (2.3)                      | 3 (1.4)                        | 14 (4.0)                   | 6 (7.0)                    |
| Osteoarthritis               | 10 (1.7)          | 13 (2.2)                      | 1 (0.5)                        | 13 (3.7)                   | 0                          |
| Joint swelling               | 10 (1.7)          | 15 (2.5)                      | 4 (1.8)                        | 10 (2.9)                   | 2 (2.3)                    |
| Condition                      | 959  | 1041 | 339  | 676  | 95   |
|--------------------------------|------|------|------|------|------|
| **Number of AEs**              |      |      |      |      |      |
| **Patients with an AE, N (%)** | 357 (60.9) | 378 (62.8) | 130 (59.4) | 221 (63.7) | 36 (41.9) |
| **Patients with serious AE, N (%)** | 21 (3.6) | 32 (5.3) | 8 (3.7) | 23 (6.6) | 0 |
| **Patients with severe AE, N (%)** | 23 (3.9) | 28 (4.7) | 13 (5.9) | 23 (6.6) | 1 (1.2) |

**Common AEs, N (%)**

| Condition                      | 959  | 1041 | 339  | 676  | 95   |
|--------------------------------|------|------|------|------|------|
| **Arthralgia**                 | 95 (16.2) | 91 (15.1) | 30 (13.7) | 53 (15.3) | 5 (5.8) |
| **Nasopharyngitis**            | 49 (8.4) | 61 (10.1) | 16 (7.3) | 31 (8.9) | 0 |
| **Back pain**                  | 32 (5.5) | 42 (7.0) | 8 (3.7) | 26 (7.5) | 1 (1.2) |
| **Osteoarthritis**             | 19 (3.2) | 22 (3.7) | 2 (0.9) | 22 (6.3) | 1 (1.2) |
| **Headache**                   | 33 (5.6) | 34 (5.6) | 8 (3.7) | 16 (4.6) | 5 (5.8) |
| Condition                      | Study A4091027 | Study A4091056 | Study A4091057 |
|--------------------------------|----------------|----------------|----------------|
| Paresthesia                    | 7 (1.2)        | 15 (2.5)       | 3 (1.4)        |
| Musculoskeletal pain           | 23 (3.9)       | 31 (5.1)       | 7 (3.2)        |
| Joint swelling                 | 13 (2.2)       | 17 (2.8)       | 6 (2.7)        |
| Pain in extremity              | 16 (2.7)       | 26 (4.3)       | 9 (4.1)        |
| Oedema peripheral              | 2 (0.3)        | 7 (1.2)        | 7 (3.2)        |
| Influenza                      | 10 (1.7)       | 14 (2.3)       | 1 (0.5)        |
| Fall                           | 21 (3.6)       | 35 (5.8)       | 9 (4.1)        |
| Upper respiratory tract infection | 13 (2.2)   | 18 (3.0)       | 10 (4.6)       |
| Cough                          | 9 (1.5)        | 9 (1.5)        | 2 (0.9)        |
| Rapidly progressive osteoarthritis | 0           | 7 (1.2)        | 1 (0.5)        |
| Hypoesthesia                   | 8 (1.4)        | 15 (2.5)       | 5 (2.3)        |
| Respiratory tract infection    | 0             | 2 (0.3)        | 0              |
| Cataract                       | 6 (1.0)        | 3 (0.5)        | 0              |
| Hypertension                   | 13 (2.2)       | 7 (1.2)        | 2 (0.9)        |
| Diarrhea                       | 9 (1.5)        | 10 (1.7)       | 8 (3.7)        |
| Peripheral swelling            | 5 (0.9)        | 4 (0.7)        | 3 (1.4)        |
| Neck pain                      | 12 (2.0)       | 9 (1.5)        | 2 (0.9)        |
| Bronchitis                     | 13 (2.2)       | 16 (2.7)       | 0              |
| Urinary tract infection        | 8 (1.4)        | 15 (2.5)       | 4 (1.8)        |
| Joint stiffness                 | 2 (0.3)        | 5 (0.8)        | 5 (2.3)        |
| Synovial cyst                  | 3 (0.5)        | 4 (0.7)        | 1 (0.5)        |
| Muscle spasms                  | 6 (1.0)        | 8 (1.3)        | 5 (2.3)        |
| Injection site reaction        | 3 (0.5)        | 2 (0.3)        | 0              |
| Rotator cuff syndrome          | 4 (0.7)        | 6 (1.0)        | 5 (2.3)        |

* Treatment period was 16, 16, and 24 weeks for studies A4091027, A4091056, and A4091057,
respectively.

† Osteoarthritis was the only serious AE that occurred in >1 patient in any treatment group (2 patients each in the placebo, tanezumab 2.5 mg, and tanezumab 5 mg groups).

‡ Arthralgia was the only AE reported as severe in >1 patient in any group (placebo n = 3; tanezumab 2.5 mg n = 1; tanezumab 5 mg n = 7).

§ The only TEAEs that led to discontinuation of treatment and/or study in >1 patient in any group were arthralgia (placebo n = 7; tanezumab 2.5 mg n = 2; tanezumab 2.5/5 mg n = 1) and OA (tanezumab 2.5 mg n = 3).

¶ Occurring in ≥2% of patients in any treatment group.

# Full study comprised both the treatment + safety follow-up periods. This was 16 + 8, 16 + 24, and 24 + 24 weeks for studies A40901027, A4091056, and A4091057, respectively.

AE = adverse event; SC = subcutaneous.
Table 4. Summary of joint safety

| N (%) patients* | Placebo (N = 514) | SC Tanezumab 2.5 mg (N = 528) | SC Tanezumab 2.5/5 mg (N = 219) | SC Tanezumab 5 mg (N = 284) |
|-----------------|-------------------|-------------------------------|---------------------------------|-----------------------------|
| **During the full study period†** |                   |                               |                                 |                             |
| Analyzed by the adjudication committee | 24 (4.7) | 41 (7.8) | 17 (7.8) | 33 (11.6) |
| Included in the composite joint safety endpoint | 0 | 10 (1.9) | 1 (0.5) | 9 (3.2) |
| Rapidly progressive osteoarthritis‡ | 0 | 9 (1.7) | 1 (0.5) | 8 (2.8) |
| Type 1 | 0 | 6 (1.1) | 1 (0.5) | 5 (1.8) |
| Type 2 | 0 | 3 (0.6) | 0 | 3 (1.1) |
| Primary osteonecrosis | 0 | 0 | 0 | 1 (0.4) |
| Subchondral insufficiency fracture | 0 | 1 (0.2) | 0 | 0 |
| Normal progression of osteoarthritis | 22 (4.3) | 30 (5.7) | 16 (7.3) | 19 (6.7) |
| Other joint outcome§ | 2 (0.4) | 1 (0.2) | 0 | 5 (1.8) |
| With ≥1 total joint replacement | 23 (4.5) | 31 (5.9) | 15 (6.8) | 20 (7.0) |

* N’s for studies A4091056 and A4091057 only, A4091027 was not included in the analysis. See methods for details.
† Full study comprised both the treatment + follow-up periods. This was 16 +24 and 24 + 24 weeks for studies A4091056 and A4091057, respectively.
Rapidly progressive osteoarthritis type 1 was defined as a significant loss of joint space width ≥2 mm (predicated on optimal joint positioning) within approximately 1 year, without gross structural failure. Rapidly progressive osteoarthritis type 2 was defined as abnormal bone loss or destruction, including limited or total collapse of at least 1 subchondral surface, which is not normally present in conventional end-stage osteoarthritis (15).

Other joint outcomes included 2 instances of pre-existing conditions in the placebo group; 1 instance of pre-existing conditions in the tanezumab 2.5 mg group; and 2 instances of pre-existing conditions, 2 instances of no change in joint, and 1 instance of posttraumatic condition in the tanezumab 5 mg group.

SC = subcutaneous.

Table 5. Summary of treatment-emergent adverse events of abnormal peripheral sensation*

| AEs | Placebo | SC Tanezumab 2.5 mg | SC Tanezumab 2.5/5 mg | SC Tanezumab 5 mg | SC Tanezumab 10 mg |
|-----|---------|---------------------|-----------------------|------------------|--------------------|
| (N = 586) |         |                     |                       |                  |                    |
|                                | (N = 602) | (N = 219) | (N = 347) | (N = 86) |
|--------------------------------|-----------|-----------|-----------|----------|
| **During the treatment period**|           |           |           |          |
| Patients with an AE, N (%)     | 13 (2.2)  | 31 (5.1)  | 7 (3.2)   | 21 (6.1) |
| Patients with serious AE, N (%)| 0         | 0         | 0         | 0        |
| Patients with severe AE, N (%)  | 0         | 0         | 0         | 0        |
| Patients discontinuing          | 0         | 0         | 0         | 1 (0.3)  |
| treatment due to an AE, N (%)   | 0         | 0         | 0         | 1 (0.3)  |
| Specific AEs, N (%)             |           |           |           |          |
| Paresthesia                    | 6 (1.0)   | 14 (2.3)  | 3 (1.4)   | 14 (4.0) |
| Hypoesthesia                   | 5 (0.9)   | 11 (1.8)  | 3 (1.4)   | 8 (2.3)  |
| Burning sensation              | 1 (0.2)   | 1 (0.2)   | 0         | 2 (0.6)  |
| Carpal tunnel syndrome         | 0         | 3 (0.5)   | 0         | 1 (0.3)  |
| Sciatica                       | 1 (0.2)   | 3 (0.5)   | 0         | 1 (0.3)  |
| Decreased vibratory sense      | 3 (0.5)   | 1 (0.2)   | 1 (0.5)   | 1 (0.3)  |
| Neuralgia                      | 0         | 1 (0.2)   | 0         | 1 (0.3)  |
| Neuropathy peripheral          | 0         | 0         | 0         | 1 (0.3)  |
| Paresthesia oral               | 0         | 0         | 0         | 1 (0.3)  |
| Hypoesthesia oral              | 1 (0.2)   | 0         | 0         | 0        |
| Sensory disturbance            | 0         | 0         | 0         | 1 (1.2)  |
| **During the full study period**|          |           |           |          |
| Patients with an AE, N (%)     | 19 (3.2)  | 41 (6.8)  | 9 (4.1)   | 24 (6.9) |
| Patients with serious AE, N (%)| 1 (0.2)   | 0         | 0         | 0        |
| Patients with severe AE, N (%)  | 1 (0.2)   | 2 (0.3)   | 0         | 0        |
| Specific AEs, N (%)             |           |           |           |          |
| Paresthesia                    | 7 (1.2)   | 15 (2.5)  | 3 (1.4)   | 14 (4.0) |
| Hypoesthesia                   | 8 (1.4)   | 15 (2.5)  | 5 (2.3)   | 8 (2.3)  |
| Sciatica                       | 4 (0.7)   | 6 (1.0)   | 0         | 3 (0.9)  |

This article is protected by copyright. All rights reserved
| Event                                      | Study A4091027 | Study A4091056 | Study A4091057 |
|--------------------------------------------|----------------|----------------|----------------|
| Burning sensation                          | 1 (0.2)        | 1 (0.2)        | 0              |
| Decreased vibratory sense                  | 3 (0.5)        | 2 (0.3)        | 1 (0.5)        |
| Carpal tunnel syndrome                     | 0              | 4 (0.7)        | 0              |
| Neuralgia                                  | 0              | 1 (0.2)        | 0              |
| Neuropathy peripheral                      | 0              | 0              | 1 (0.3)        |
| Paresthesia oral                           | 0              | 0              | 1 (0.3)        |
| Sensory loss                               | 1 (0.2)        | 1 (0.2)        | 0              |
| Dysesthesia                                | 0              | 1 (0.2)        | 0              |
| Hypoesthesia oral                          | 1 (0.2)        | 0              | 0              |
| Sensory disturbance                        | 0              | 0              | 0              |

*Events of abnormal peripheral sensation could include the terms of allodynia, axonal neuropathy, burning sensation, carpal tunnel syndrome, decreased vibratory sense, demyelinating polyneuropathy, dysesthesia, formication, hyperesthesia, hyperpathia, hypoesthesia, hypoesthesia oral, intercostal neuralgia, neuralgia, neuritis, neuropathy peripheral, paresthesia, paresthesia oral, peripheral sensorimotor neuropathy, peripheral sensory neuropathy, polyneuropathy, polyneuropathy chronic, sciatica, sensory disturbance, sensory loss, tarsal tunnel syndrome, or thermohypoesthesia.

† Treatment period was 16, 16, and 24 weeks for studies A4091027, A4091056, and A4091057, respectively.

‡ Full study comprised both the treatment + safety follow-up periods. This was 16 + 8, 16 + 24, and 24 + 24 weeks for studies A40901027, A4091056, and A4091057, respectively.

AE = adverse event; SC = subcutaneous.
Table 6. Summary of treatment-emergent adverse events potentially associated with sympathetic neuropathy.

| AEs                          | Placebo (N = 514)* | SC Tanezumab 2.5 mg (N = 528) | SC Tanezumab 2.5/5 mg (N = 219) | SC Tanezumab 5 mg (N = 284) |
|------------------------------|--------------------|-------------------------------|--------------------------------|----------------------------|
| During the treatment period† |                    |                               |                                |                            |
| Patients with an AE, N (%)   | 4 (0.8)            | 8 (1.5)                       | 1 (0.5)                        | 8 (2.8)                    |
| Patients with serious AE, N (%) | 0                  | 0                             | 0                              | 0                          |
| Patients with severe AE, N (%) | 0                  | 0                             | 0                              | 0                          |
| Patients discontinuing       | 0                  | 0                             | 0                              | 0                          |
| treatment due to an AE, N (%) | 0                  | 0                             | 0                              | 0                          |
| Specific AEs, N (%)          |                    |                               |                                |                            |
| Bradycardia                  | 3 (0.6)            | 4 (0.8)                       | 0                              | 4 (1.4)                    |
| Orthostatic hypotension      | 1 (0.2)            | 3 (0.6)                       | 1 (0.5)                        | 3 (1.1)                    |
| Syncope                      | 0                  | 0                             | 0                              | 1 (0.4)                    |
| Hypohidrosis                 | 0                  | 1 (0.2)                       | 0                              | 0                          |
| Anhidrosis                   | 0                  | 0                             | 0                              | 0                          |
| During the full study period‡|                    |                               |                                |                            |

This article is protected by copyright. All rights reserved
| ABX 72177  | ABX 72179  | ABX 72180 | ABX 72181 |
|-----------|-----------|-----------|-----------|
| **Patients with an AE, N (%)** | 8 (1.6) | 12 (2.3) | 2 (0.9) | 11 (3.9) |
| **Patients with serious AE, N (%)** | 0 | 0 | 0 | 0 |
| **Patients with severe AE, N (%)** | 0 | 0 | 0 | 0 |
| **Specific AEs, N (%)** | | | | |
| Bradycardia | 7 (1.4) | 7 (1.3) | 1 (0.5) | 6 (2.1) |
| Orthostatic hypotension | 1 (0.2) | 4 (0.8) | 1 (0.5) | 4 (1.4) |
| Syncope | 0 | 0 | 0 | 1 (0.4) |
| Hypohidrosis | 0 | 1 (0.2) | 0 | 0 |
| Anhidrosis | 0 | 0 | 0 | 0 |

* N’s for studies A4091056 and A4091057 only, A4091027 was not included in the analysis. See methods for details.
† Treatment period was 16 and 24 weeks for studies A4091056 and A4091057, respectively.
‡ Full study comprised both the treatment + safety follow-up periods. This was 16 + 24 and 24 + 24 weeks for studies A4091056 and A4091057, respectively.

AE = adverse event; SC = subcutaneous.